{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sato T"],"funding":["JSPS KAKENHI","The Food Safety Commission of Japan","GSK Japan Research Grant 2016","Yuasa Memorial Fundation"],"pagination":["e00864-18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6125499"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(9)"],"pubmed_abstract":["Colistin is a last-line drug for multidrug-resistant Gram-negative bacteria. We previously reported four plasmid-mediated colistin resistance (<i>mcr</i>) gene-negative colistin-resistant <i>Escherichia coli</i> clinical isolates, including the major pathogenic and fluoroquinolone-resistant strains O25b:H4-ST131-<i>H</i>30Rx (isolates SRE34 and SRE44; MIC for colistin = 16 mg/liter), non-x (SME296; MIC = 8 mg/liter), and O18-ST416 (SME222; MIC = 4 mg/liter). In this study, we investigated the colistin resistance mechanism and identified novel amino acid substitutions or deletions in the PmrAB two-component system that activates <i>eptA</i> (encoding a phosphoethanolamine transferase) and <i>arnT</i> (encoding an undecaprenyl phosphate-alpha-4-amino-4-deoxy-l-arabinose arabinosyl transferas"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Contribution of Novel Amino Acid Alterations in PmrA or PmrB to Colistin Resistance in <i>mcr</i>-Negative Escherichia coli Clinical Isolates, Including Major Multidrug-Resistant Lineages O25b:H4-ST131-<i>H</i>30Rx and Non-x."],"pmcid":["PMC6125499"],"funding_grant_id":["17K15688","1703"],"pubmed_authors":["Shiraishi T","Kuronuma K","Hiyama Y","Sato T","Shinagawa M","Takahashi S","Usui M","Tamura Y","Masumori N","Honda H","Yokota SI"],"additional_accession":[]},"is_claimable":false,"name":"Contribution of Novel Amino Acid Alterations in PmrA or PmrB to Colistin Resistance in <i>mcr</i>-Negative Escherichia coli Clinical Isolates, Including Major Multidrug-Resistant Lineages O25b:H4-ST131-<i>H</i>30Rx and Non-x.","description":"Colistin is a last-line drug for multidrug-resistant Gram-negative bacteria. We previously reported four plasmid-mediated colistin resistance (<i>mcr</i>) gene-negative colistin-resistant <i>Escherichia coli</i> clinical isolates, including the major pathogenic and fluoroquinolone-resistant strains O25b:H4-ST131-<i>H</i>30Rx (isolates SRE34 and SRE44; MIC for colistin = 16 mg/liter), non-x (SME296; MIC = 8 mg/liter), and O18-ST416 (SME222; MIC = 4 mg/liter). In this study, we investigated the colistin resistance mechanism and identified novel amino acid substitutions or deletions in the PmrAB two-component system that activates <i>eptA</i> (encoding a phosphoethanolamine transferase) and <i>arnT</i> (encoding an undecaprenyl phosphate-alpha-4-amino-4-deoxy-l-arabinose arabinosyl transferas","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2026-04-14T19:06:29.438Z","creation":"2019-06-06T20:07:27Z"},"accession":"S-EPMC6125499","cross_references":{"pubmed":["29914952"],"doi":["10.1128/AAC.00864-18","10.1128/aac.00864-18"]}}